INTRODUCTION: A personal history of basal cell carcinoma (BCC) is associated with increased risk of other malignancies, but the reason is unknown. The hedgehog pathway is critical to the etiology of BCC, and is also believed to contribute to susceptibility to other cancers. This study tested the hypothesis that hedgehog pathway and pathway-related gene variants contribute to the increased risk of subsequent cancers among those with a history of BCC. METHODS: The study was nested within the ongoing CLUE II cohort study, established in 1989 in Washington County, Maryland, USA. The study consisted of a cancer-free control group (n=2296) compared to three different groups of cancer cases ascertained through 2007, those diagnosed with: (1) Other (non-BCC) cancer only (n=2349); (2) BCC only (n=534); and (3) BCC plus other cancer (n=446). The frequencies of variant alleles were compared among these four groups for 20 single nucleotide polymorphisms (SNPs) in 6 hedgehog pathway genes (SHH, IHH, PTCH2, SMO, GLI1, SUFU), and also 22 SNPs in VDR and 8 SNPs in FAS, which have cross-talk with the hedgehog pathway. RESULTS: Comparing those with both BCC and other cancer versus those with no cancer, no significant associations were observed for any of the hedgehog pathway SNPs, or for the FAS SNPs. One VDR SNP was nominally significantly associated with the BCC cancer-prone phenotype, rs11574085 [per minor allele odds ratio (OR) 1.38, 95% confidence interval (CI) 1.05-1.82; p-value=0.02]. CONCLUSION: The hedgehog pathway gene SNPs studied, along with the VDR and FAS SNPs studied, are not strongly associated with the BCC cancer-prone phenotype.
INTRODUCTION: A personal history of basal cell carcinoma (BCC) is associated with increased risk of other malignancies, but the reason is unknown. The hedgehog pathway is critical to the etiology of BCC, and is also believed to contribute to susceptibility to other cancers. This study tested the hypothesis that hedgehog pathway and pathway-related gene variants contribute to the increased risk of subsequent cancers among those with a history of BCC. METHODS: The study was nested within the ongoing CLUE II cohort study, established in 1989 in Washington County, Maryland, USA. The study consisted of a cancer-free control group (n=2296) compared to three different groups of cancer cases ascertained through 2007, those diagnosed with: (1) Other (non-BCC) cancer only (n=2349); (2) BCC only (n=534); and (3) BCC plus other cancer (n=446). The frequencies of variant alleles were compared among these four groups for 20 single nucleotide polymorphisms (SNPs) in 6 hedgehog pathway genes (SHH, IHH, PTCH2, SMO, GLI1, SUFU), and also 22 SNPs in VDR and 8 SNPs in FAS, which have cross-talk with the hedgehog pathway. RESULTS: Comparing those with both BCC and other cancer versus those with no cancer, no significant associations were observed for any of the hedgehog pathway SNPs, or for the FAS SNPs. One VDR SNP was nominally significantly associated with the BCC cancer-prone phenotype, rs11574085 [per minor allele odds ratio (OR) 1.38, 95% confidence interval (CI) 1.05-1.82; p-value=0.02]. CONCLUSION: The hedgehog pathway gene SNPs studied, along with the VDR and FAS SNPs studied, are not strongly associated with the BCC cancer-prone phenotype.
Authors: Paul I W de Bakker; Roman Yelensky; Itsik Pe'er; Stacey B Gabriel; Mark J Daly; David Altshuler Journal: Nat Genet Date: 2005-10-23 Impact factor: 38.330
Authors: R C Strange; N El-Genidy; S Ramachandran; T J Lovatt; A A Fryer; A G Smith; J T Lear; C Wong; P W Jones; F Ichii-Jones; P R Hoban Journal: Ann Hum Genet Date: 2004-11 Impact factor: 1.670
Authors: A Asplund; A C Gustafsson; N M Wikonkal; A Sela; D J Leffell; K Kidd; J Lundeberg; D E Brash; F Pontén Journal: Br J Dermatol Date: 2005-05 Impact factor: 9.302
Authors: Meng Chen; Michelle A T Hildebrandt; Jessica Clague; Ashish M Kamat; Antoni Picornell; Joshua Chang; Xiaofan Zhang; Julie Izzo; Hushan Yang; Jie Lin; Jian Gu; Stephen Chanock; Manolis Kogevinas; Nathaniel Rothman; Debra T Silverman; Montserrat Garcia-Closas; H Barton Grossman; Colin P Dinney; Núria Malats; Xifeng Wu Journal: Cancer Prev Res (Phila) Date: 2010-09-21
Authors: Arnaud E Teichert; Hashem Elalieh; Peter M Elias; JoEllen Welsh; Daniel D Bikle Journal: J Invest Dermatol Date: 2011-08-04 Impact factor: 8.551
Authors: Lisa Gallicchio; Howard H Chang; Dana K Christo; Lucy Thuita; Han Yao Huang; Paul Strickland; Ingo Ruczinski; Sandra Clipp; Kathy J Helzlsouer Journal: BMC Med Genet Date: 2009-10-09 Impact factor: 2.103
Authors: Andrea Watson; Paul Kent; Murad Alam; Amy S Paller; David M Umbach; Joon Won Yoon; Philip M Iannaccone; David O Walterhouse Journal: Mol Cancer Date: 2009-11-30 Impact factor: 27.401
Authors: Carolina Morgado-Águila; Purificación Rey-Sánchez; Guadalupe Gil-Fernández; María Carmen Costa-Fernández; Francisco José Rodríguez-Velasco Journal: J Clin Med Date: 2020-11-25 Impact factor: 4.241
Authors: Judy R Rees; M Scot Zens; Jiang Gui; Maria O Celaya; Bruce L Riddle; Margaret R Karagas Journal: PLoS One Date: 2014-06-17 Impact factor: 3.240